Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cellyan Biotechnology CoHKPD -4.33%21 EV-to-FCF is -19.66 as of Jul. 14, 2026. GuruFocus rates HKPD with a GF Score™ of 21/100. The stock has 2 warning signs investors should review. Among 73 Medical Distribution companies, Cellyan Biotechnology Co ranks worse than 1369861.64% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cellyan Biotechnology Co's Enterprise Value is $10.20 Mil.
Cellyan Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.52 Mil. Therefore, Cellyan Biotechnology Co's EV-to-FCF for today is -19.66.
The historical rank and industry rank for Cellyan Biotechnology Co's EV-to-FCF or its related term are showing as below:
HKPD'
s EV-to-FCF Range Over the Past 10 Years
Min: -65.8 Med: 18.17 Max: 42.85
Current: -19.66
During the past 3 years, the highest EV-to-FCF of Cellyan Biotechnology Co was 42.85. The lowest was -65.80. And the median was 18.17.
HKPD's EV-to-FCF is ranked worse than 100% of 73
companies
in the Medical Distribution industry
Industry Median: 17.47
vs HKPD: -19.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cellyan Biotechnology Co (NAS:HKPD) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cellyan Biotechnology Co's PE Ratio (TTM) for today is calculated as:
Cellyan Biotechnology Co's share price for today is $0.443.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cellyan Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.064.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cellyan Biotechnology Co EV-to-FCF Related Terms
Cellyan Biotechnology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, Cellyan Biotechnology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cellyan Biotechnology Co EV-to-FCF vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Cellyan Biotechnology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cellyan Biotechnology Co's EV-to-FCF falls into.
Cellyan Biotechnology Co's current Enterprise Value is $10.20 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cellyan Biotechnology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was $-0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cellyan Biotechnology Co (HKPD) has a EV-to-FCF of -19.66 as of Jul. 14, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cellyan Biotechnology Co and its competitors. According to the industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 73 companies in the Medical Distribution industry.
Is Cellyan Biotechnology Co's EV-to-FCF too high?
Cellyan Biotechnology Co's current EV-to-FCF is -19.66. Based on the distribution chart, Cellyan Biotechnology Co ranks #999999 out of 73 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Cellyan Biotechnology Co has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Cellyan Biotechnology Co's EV-to-FCF compare to COSM and SNYR?
According to the Medical Distribution industry distribution chart, Cellyan Biotechnology Co ranks #999999 out of 73 companies for EV-to-FCF. This places Cellyan Biotechnology Co in the lower half of its industry. The industry median EV-to-FCF is 17.47. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Distribution company?
The median EV-to-FCF among Medical Distribution companies is 17.47, based on 73 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Cellyan Biotechnology Co and its competitors. For the Medical Distribution industry, the median EV-to-FCF is 17.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cellyan Biotechnology Co's current EV-to-FCF is -19.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cellyan Biotechnology Co stock overvalued right now?
Cellyan Biotechnology Co (HKPD) has a current EV-to-FCF of -19.66. The current EV-to-FCF is -19.66. Cellyan Biotechnology Co's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Cellyan Biotechnology Co (HKPD), the current EV-to-FCF is -19.66 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cellyan Biotechnology Co Ltd formerly, Hong Kong Pharma Digital Technology Holdings Ltd operates in two main categories: OTC pharmaceutical cross-border e-commerce supply chain services, conducted through its Hong Kong subsidiary, Joint Cross Border, which it refers to as the Supply Chain Services division, and OTC pharmaceutical cross-border procurement and distribution, conducted through its Hong Kong subsidiary, V-Alliance, which it referred to as the Procurement and Distribution division. Based in Hong Kong, Joint Cross Border has established itself as a provider of third-party supply chain services in Mainland China's OTC pharmaceutical cross-border e-commerce market.
21GF Score
Get the complete analysis for HKPD
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKPD has been successfully added to your 
